[Osteoporosis: Novel drug, new recommendations].

Autor:	Bégin MJ; Service des maladies osseuses, Département des spécialités de médecine, HUG, 1211 Genève 14., Uebelhart B; Service des maladies osseuses, Département des spécialités de médecine, HUG, 1211 Genève 14., Biver E; Service des maladies osseuses, Département des spécialités de médecine, HUG, 1211 Genève 14., Ferrari S; Service des maladies osseuses, Département des spécialités de médecine, HUG, 1211 Genève 14.
Jazyk:	francouzština
Zdroj:	Revue medicale suisse [Rev Med Suisse] 2021 Jan 13; Vol. 17 (720-1), pp. 63-67.
Abstrakt:	New recommendations from the Swiss Association against Osteoporosis (SVGO) concerning fracture risk stratification and treatment delineate two new risk categories : very high risk (FRAX 10-years probability of fracture at least 20 % above the usual intervention threshold) and imminent risk (major osteoporotic fracture in the last 2 years). In these patients, parenteral therapies are recommended first. Among them, romosozumab is now available in Switzerland and is indicated for 1 year in absence of cardiovascular contra-indications, followed by an anti-resorptive. Regarding denosumab, several studies indicate that post-treatment bone loss may be, at least partially, prevented by zoledronate. Finally, monitoring BMD changes and the T-score reached on any therapy could be used as an indicator of anti-fracture efficacy. Competing Interests: Le Dr Emmanuel Biver a des contacts avec Nestlé, AMGEN et Labatec. Le Pr Serge Ferrari a des contacts avec AMGEN, UCB, Agnovos, Radius et Labatec. Les autres auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu